• In June 2026, DuPont de Nemours, Inc. implemented a 1-for-3 reverse stock split, reduced its authorized share count, affirmed a US$0.60 quarterly dividend, and was added to the Russell 1000 Defensive and Russell 1000 Value-Defensive Indexes.
• These changes collectively reposition DuPont’s equity profile, potentially affecting index-tracking fund ownership, perceived defensiveness, and how investors evaluate its capital structure and income profile.
• We’ll now examine how DuPont’s inclusion in the Russell 1000 Defensive Index influences the company’s existing investment narrative and risk profile.

Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

DuPont de Nemours Investment Narrative Recap

To own DuPont today, you need to believe in its pivot toward higher value electronics, healthcare, and water solutions while it manages PFAS litigation and portfolio reshaping. The reverse split, reduced share authorization, and Russell defensive index inclusions mainly refine how the stock trades and screens; they do not materially change near term catalysts around Qnity’s separation or the key risk of ongoing environmental and regulatory costs.

The most relevant recent announcement is DuPont’s 1-for-3 reverse stock split with a matching cut in authorized shares. For investors focused on catalysts, this cleanly resets the share count ahead of portfolio moves and may interact with the Qnity spin and any future buybacks, affecting per share metrics and how funds benchmarked to defensive and value indices assess the company’s risk and income profile.

Yet behind the more optimistic forecasts that earnings could reach about US$995 million by 2029, investors should be aware of how PFAS litigation and rising ESG costs could still...

DuPont de Nemours' narrative projects $7.8 billion revenue and $919.6 million earnings by 2029. This requires 4.3% yearly revenue growth and about a $787.6 million earnings increase from $132.0 million today.

Uncover how DuPont de Nemours' forecasts yield a $172.07 fair value, a 23% upside to its current price.

Exploring Other Perspectives

While the consensus narrative focuses on portfolio focus and PFAS risk, the most optimistic analysts were already modeling about US$8.0 billion in 2029 revenue and much higher margins, reminding you that opinions can diverge sharply and that this new index inclusion and capital structure shift may ultimately push those expectations, and the ESG and substitution risk story, in very different directions.

Explore 4 other fair value estimates on DuPont de Nemours - why the stock might be worth less than half the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your DuPont de Nemours research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free DuPont de Nemours research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DuPont de Nemours' overall financial health at a glance.

Interested In Other Possibilities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.